WoodTrust Financial Corp increased its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 10.9% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 91,970 shares of the company’s stock after purchasing an additional 9,033 shares during the quarter. Johnson & Johnson comprises about 1.5% of WoodTrust Financial Corp’s holdings, making the stock its 11th largest position. WoodTrust Financial Corp’s holdings in Johnson & Johnson were worth $14,549,000 as of its most recent filing with the SEC.
Other hedge funds also recently made changes to their positions in the company. Keener Financial Planning LLC bought a new stake in Johnson & Johnson during the fourth quarter valued at $40,000. WFA Asset Management Corp boosted its stake in Johnson & Johnson by 61.4% during the fourth quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock valued at $40,000 after buying an additional 97 shares during the period. Vermillion & White Wealth Management Group LLC bought a new stake in Johnson & Johnson during the fourth quarter valued at $44,000. Disciplined Equity Management Inc. bought a new stake in Johnson & Johnson during the fourth quarter valued at $45,000. Finally, Grayhawk Investment Strategies Inc. boosted its stake in Johnson & Johnson by 528.6% during the fourth quarter. Grayhawk Investment Strategies Inc. now owns 308 shares of the company’s stock valued at $48,000 after buying an additional 259 shares during the period. 69.55% of the stock is currently owned by hedge funds and other institutional investors.
Johnson & Johnson Stock Up 0.2 %
Shares of NYSE:JNJ opened at $146.16 on Friday. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $175.97. The company has a market cap of $351.76 billion, a PE ratio of 9.11, a P/E/G ratio of 2.43 and a beta of 0.53. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.17 and a quick ratio of 0.94. The stock’s 50-day moving average is $148.14 and its 200 day moving average is $154.06.
Johnson & Johnson Increases Dividend
The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st were issued a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.39%. The ex-dividend date of this dividend was Monday, May 20th. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.19. Johnson & Johnson’s payout ratio is currently 30.92%.
Wall Street Analyst Weigh In
Several brokerages have issued reports on JNJ. HSBC raised Johnson & Johnson from a “hold” rating to a “buy” rating and lifted their price target for the stock from $169.00 to $170.00 in a research note on Thursday, April 18th. Morgan Stanley dropped their price target on Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 17th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $175.00 price target on shares of Johnson & Johnson in a research note on Monday, June 17th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Sunday. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research note on Thursday, June 20th. Eight investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $174.07.
Get Our Latest Stock Analysis on Johnson & Johnson
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
Recommended Stories
- Five stocks we like better than Johnson & Johnson
- How to Start Investing in Real Estate
- Upwork Stock’s Outlook: Numbers Solid Despite Gen-AI Challenges
- 5 Top Rated Dividend Stocks to Consider
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- MarketBeat Week in Review – 6/24 – 6/28
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.